TG Therapeutics, Inc. (TGTX) Stock: Price, Forecast & Analyst Target
TG Therapeutics, Inc. (TGTX) — MoonshotScore 90/100 (Exceptional band), calculated Nov 18, 2026. Price $64.88 (-1.88%), as of the Nov 19, 2026 trading session; market cap $9.81B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 19.44× (cash as of Sep 30, 2026) · expected results Feb 25, 2027
TG Therapeutics, Inc. · TGTX · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): TG Therapeutics is a commercial-stage biopharmaceutical company whose reported revenue now comes overwhelmingly from product sales rather than licensing or royalty income. The case depends on whether rising product demand can continue to outrun expanding research and commercial spending while turning uneven cash generation into a durable pattern.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · TG Therapeutics (TGTX)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Rich; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 2 of the last 8 reports
- Altman Z 6.34 · Piotroski F 6
- ROE 17.6% · ROA 6.7% · current ratio 4.50 · earnings yield 1.2% · free-cash-flow yield 0.9%
Holding back: a rich price
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 76 | Strong | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional | |
| 90 | Exceptional | |
| 90 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $64.88 | |
| Change on the day | -1.88% | |
| 52-week range | $26.76–$68.03 | |
| Market capitalisation | $9.81B | — |
| Price / earnings (trailing) | 84.19 | |
| Shares traded on the day | 1.66M | |
| Beta (volatility vs the S&P 500) | 1.81 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings call · management outlook
- · Earnings results · below the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
Our core business metrics support our increased full year U.S. revenue guidance of $915 million to $920 million and our expectation for a strong fourth quarter and full year 2026.
Adam Waldman · Statement from
On spending, we continue to expect full-year R&D and SG&A expenses, excluding stock-based comp, to be in line with our prior guidance of $450 million-$500 million, inclusive of those subcutaneous BRIUMVI manufacturing and secondary source manufacturer startup activities.
Sean Power · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for TG Therapeutics (TGTX): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 16, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is TG Therapeutics (TGTX), and what does it report?
Short answer · as of
TG Therapeutics acquires, develops and markets therapies aimed at autoimmune disorders and B-cell malignancies.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Its portfolio includes ublituximab, a glycoengineered monoclonal antibody, alongside antibody and oral drug candidates directed at immune and cancer targets.
The biotechnology label invites a pipeline-first reading, but the reported business is already product-led. Product revenue accounts for nearly all sales, while royalties, licensing and other revenue remain peripheral; consolidated revenue therefore measures commercial uptake far more than milestone-driven deal activity.
What do the latest results show for TG Therapeutics (TGTX)?
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Revenue and gross profit reached fresh sequential highs in the latest reported period. Operating profit and net income nevertheless retreated as research spending surged, showing that stronger sales did not translate proportionately into earnings.
Revenue exceeded the prevailing estimate while earnings fell well short of it. Management expects growth to lean toward the closing quarter and says spending reflects continued investment in the commercial organization and direct-to-consumer efforts; that is management’s explanation, while the reported accounts show the immediate mechanism was heavier research expense.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $259.94M Sep 30, 2026
- Latest quarter · R&D
- $51.29M Sep 30, 2026
- Latest quarter · SG&A
- $80.67M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $85.90M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $259.94M | $51.29M | $80.67M | $85.90M |
| Jun 30, 2026 | $240.34M | $95.34M | $82.13M | $21.67M |
| Mar 31, 2026 | $204.92M | $48.40M | $88.22M | $34.80M |
| Dec 31, 2025 | $192.57M | $41.19M | $62.74M | $50.49M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $259.94M Nov 9, 2026
- Latest report · revenue estimate
- $245.47M Nov 9, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 9, 2026
- Latest report · EPS vs estimate
- Below estimate Nov 9, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 9, 2026 | $259.94M | $245.47M | $0.3500 | $0.3593 |
| Aug 3, 2026 | $240.34M | $229.77M | $0.0500 | $0.3057 |
| May 6, 2026 | $204.92M | $200.33M | $0.1400 | $0.2300 |
| Feb 26, 2026 | $192.57M | $191.79M | $0.1400 | $0.3500 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $260M | $55M | $0.35 (diluted) |
| Q2 FY2026 | $240M | $8M | $0.05 (diluted) |
| Q1 FY2026 | $205M | $20M | $0.12 (diluted) |
| Q4 FY2025 | $193M | $23M | $0.14 (diluted) |
What are the financial strengths and risks for TG Therapeutics (TGTX)?
Short answer
Cash and short-term investments were $504.67M at the Sep 30, 2026 balance-sheet date. Operating cash flow was $45.23M for the quarter ended Sep 30, 2026, meaning operations generated cash. These figures do not establish a cash runway.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Liquidity is substantial relative to recent operating cash use, and short-term solvency ratios indicate ample coverage of near-term obligations. The latest period produced positive operating cash flow after an alternating pattern of inflows and outflows, so cash conversion has improved without yet becoming dependable.
Debt exceeds cash and short-term investments, leaving TG Therapeutics in a net-debt position despite its large liquidity reserve. Earnings quality also warrants attention because a prior quarterly net result stood far above operating profit; the resulting annual profit should not be treated as a clean picture of recurring operations.
The practical risk is expense absorption: gross profit is growing, but research and commercial investment can consume that progress before it reaches operating cash flow. A runway cross-check indicates considerable funding capacity at the recent rate of cash use, yet sustained product growth matters more than the runway calculation because leverage remains material.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Rich valuation — a P/E of 84.19 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- $45.23M Sep 30, 2026
- Previous quarter · operating cash flow
- $39.26M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | $45.23M | −$280,000 |
| Jun 30, 2026 | $39.26M | −$290,000 |
| Mar 31, 2026 | −$17.89M | −$50,000 |
| Dec 31, 2025 | $19.66M | −$70,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at TG Therapeutics (TGTX)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Watch whether revenue accelerates into the closing quarter as management expects, and whether gross-profit growth again exceeds the combined pressure from research and commercial spending. The useful confirmation would be concurrent progress in operating profit and operating cash flow, not revenue growth alone.
Consensus forecasts assume continued expansion in revenue and earnings across the available horizon. The nearer test is the scheduled earnings release: another revenue beat paired with an earnings shortfall would reinforce the pattern of successful commercial growth being reinvested faster than it reaches shareholders’ earnings.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
Yeah, I think it's fair to say we'll expect to launch in the second mid-2027.
Adam Waldman ·
So taken together, all that supports our expectation for a strong fourth quarter and another raise to our full year guidance here.
Adam Waldman ·
How does TG Therapeutics compare with its peers?
Short answer
TG Therapeutics's score ranks 9th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
TG Therapeutics differs from a development-stage biotechnology company because product sales already dominate revenue and operations are profitable. Its valuation and operating results therefore respond to commercial execution as well as clinical development.
It also differs from a diversified pharmaceutical business: royalties, licensing and other income contribute little beside product revenue, while research spending remains substantial and the portfolio extends across autoimmune disease and B-cell malignancies. That combination creates high gross margins and meaningful operating leverage, but also concentrates the financial story around continued uptake of marketed therapy and disciplined portfolio investment.
| Company | Price | Market value | Score |
|---|---|---|---|
| $93.53 Nov 19, 2026 | $7.35B | 98 5-pillar Nov 18, 2026 | |
| $65.83 Nov 19, 2026 | $16.1B | 98 5-pillar Nov 18, 2026 | |
| $315.82 Nov 19, 2026 | $9.36B | 96 5-pillar Nov 18, 2026 | |
| $255.96 Nov 19, 2026 | $16.8B | 96 5-pillar Nov 18, 2026 | |
| $93.04 Nov 19, 2026 | $10.6B | 95 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $72.70 Nov 19, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| TG Therapeutics (TGTX) — this page | $64.88 | $9.81B | 90 |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $97.57 Nov 19, 2026 | $6.62B | 67 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $78.00 – $83.00
- Consensus target
- $80.50
- Median target
- $80.50
Consensus record · Captured .
Measured against a quoted price of $64.88 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 10, 2026
- Transactions
- 9
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 1
- Other transactions
- 8
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Institutional ownership
- 82.2% Period end Sep 30, 2026
- Previous quarter · ownership
- 79.4% Prior to period end Sep 30, 2026
- Reporting holders
- 482 Period end Sep 30, 2026
- Previous quarter · holders
- 465 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 22,634,933 |
| State Street Corp | 8,488,874 |
| Vanguard Portfolio Management LLC | 7,880,546 |
| Vanguard Capital Management LLC | 6,256,425 |
| Geode Capital Management, LLC | 3,703,676 |
Tracked investors
Which of the 16 named investors we follow held TGTX in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.14% | $32.72M | Added +36.5% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about TG Therapeutics (TGTX)?
What Investors Ask About TG Therapeutics (TGTX) — Healthcare
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What role does ublituximab play at TG Therapeutics?
Ublituximab is a glycoengineered monoclonal antibody associated with TG Therapeutics’ work in relapsing multiple sclerosis and B-cell malignancies. It connects the company’s commercial-stage identity with its broader immune and oncology development focus.
Why can TG Therapeutics revenue rise while earnings weaken?
Research expense can rise faster than gross profit, as occurred in the latest reported period. Revenue advanced and selling expense eased, yet heavier research spending reduced operating and net profit.
Are TG Therapeutics product sales producing operating cash?
The latest period generated operating cash, but preceding periods alternated between use and generation. Product-led revenue growth has therefore reached cash flow without establishing consistent conversion.
How does TG Therapeutics commercial spending shape its outlook?
Management is investing in its commercial organization and direct-to-consumer activity while expecting growth to strengthen later in the year. The relevant test is whether that spending produces enough additional product revenue to expand operating profit and cash flow.
What is the TGTX stock price today?
The last price recorded for TG Therapeutics, Inc. (TGTX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the TGTX price target?
The analyst consensus price target for TG Therapeutics, Inc. (TGTX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 81 figures on this page — 2 from SEC filings and earnings calls, 71 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com